Enveric Biosciences (ENVB) Fundamental Analysis: Revenue, Earnings & Valuation

0.94 / 10

Underperform

ENVB's fundamental score is 0.9/10, reflecting significant concerns. Key weaknesses include a high Days Sales Outstanding of 148.87 days and low Interest Coverage Ratio, although Total Operating Revenue grew 105.67% YoY. The mixed factor performance underscores the need for careful fundamental scrutiny before investment.

Analysis Checks(3/4)

Total operating revenue (YoY growth rate %)

Value105.67

Score2/3

Weight-119.73%

1M Return1.11%

Days sales outstanding

Value148.87

Score1/3

Weight154.05%

1M Return-1.57%

Interest coverage ratio (EBIT / Interest expense) (%)

Value66.08

Score2/3

Weight111.81%

1M Return-1.11%

Operating revenue (YoY growth rate %)

Value137.95

Score2/3

Weight-46.13%

1M Return0.43%

Is ENVB undervalued or overvalued?

ENVB scores 0.94/10 on fundamentals and holds a Premium valuation at present. Backed by its -320.51% ROE, 0.00% net margin, -0.29 P/E ratio, 0.95 P/B ratio, and 51.44% earnings growth, these metrics solidify its Underperform investment rating.